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Increased oxidative stress and pro-inflammatory conditions, commonly present in chronic dialysis patients, are
thought to be enhanced during hemodialysis (HD) and to be associated with the excess morbidity and mortality
seen in these patients. The hydrogen molecule (H2) has a unique biological capacity to act as an antioxidative and
anti-inflammatory substance. In light of accumulating evidence from animal studies showing protective effects
against organ damage during ischemia and inflammation, development of H2 treatments for HD patients has
become a challenging clinical goal.
An HD system utilizing a water electrolysis technique that renders large amounts of H2-enriched water has been
developed. During HD with an H2-enriched solution (approximately 50 ppb H2), markers of increased oxidative
stress (such as interleukin-6, myeloperoxidase, methemoglobin, increased lymphocyte apoptosis, and high blood
pressure) are suppressed. These findings indicate that the use of an H2-enriched solution may prove to be a novel
approach to ameliorate dialysis-related complications. This manuscript reviews the recent progress in H2 research
and the use of H2 in HD patients, including a description of a water electrolysis technique that delivers large
amounts of H2-enriched water for use in clinical settings.
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Enhanced oxidative stress and pro-inflammatory condi-
tions are common in chronic dialysis patients and are
thought to be associated with the excess morbidity and
mortality of these patients [1–3]. Given concurrent
underlying clinical conditions, multiple factors play a
role in the pathology involved, such as uremic solute ac-
cumulation, which enhances the oxidative response [4],
including indoxylsulfate [5]; accumulation of advanced
glycation end products [6], AOPP [7], methylglyoxal [8,
9], and trans-aconitate [10]; excessive spontaneous
respiratory neutrophil apoptosis [11, 12], which causes
the release of myeloperoxidase (MPO) into the blood
[13]; disturbed antioxidative systems occurring during
progressive uremia, including decreased production of* Correspondence: masanaka@fmu.ac.jp
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(http://creativecommons.org/publicdomain/zehydrogen sulfide [14] and suppressed Nrf2 activation
[15]; and activation of monocytes [16] with loss of anti-
oxidative capacity [17] during the hemodialysis (HD)
procedure. Therefore, the development of antioxidant
therapies has been recognized as a high priority for dia-
lysis patients. Currently available agents are limited to
tocopherol [18–20] and N-acetylcysteine [7, 21], and evi-
dence of their efficacy has not been established in the
clinical setting.
Recently, it has been shown that the hydrogen
molecule (H2) has a unique biological capacity as an
antioxidative and anti-inflammatory substance [22].
Evidence that H2 administration ameliorates organ
damage in various models of ischemia and inflamma-
tion has been accumulating [23]. For this reason,
clinical applications of H2 for pro-inflammatory dis-
orders are under active investigation, particularly for
use during HD therapy [24–29].
This manuscript reviews recent progress in H2 re-
search and details the applicability of a water electrolysisicle is distributed under the terms of the Creative Commons Attribution 4.0
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Fig. 1 Summary of the molecular effect of H2 on oxidative stress,
inflammation, and apoptosis. Effects of H2 as an antioxidant and
anti-inflammatory molecule are summarized. Accumulating evidence
from animal studies has revealed that H2 is a biologically active gas,
increasing antioxidative molecules, while decreasing oxidative
markers, pro-inflammatory molecules, and apoptosis in affected
organs and tissues
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of H2-enriched water for the clinical HD setting.
The hydrogen gas molecule as a biological
antioxidant
Biological effects of H2 and primary mechanism of its action
In 2007, Ohsawa et al. [22] first reported that pretreat-
ment with H2 inhalation ameliorated brain lesions after
cerebral infarction in rats. Thereafter, accumulating evi-
dence from animal studies indicated a protective effect
of H2 pretreatment on the progression of organ damage
in various types of disease models [30–69], such as
ischemia-induced injury and dysfunction of the brain
[22, 33, 39, 55, 59, 62–64], heart [34, 45, 59, 65], liver
[30], retina [41], and kidney [59, 60]; stress-induced
hippocampus dysfunction [38]; cisplatinum nephropathy
[37, 44]; transplanted intestinal graft [31, 47]; corneal al-
kali burn [51]; ouabain-induced auditory neuropathy
[66]; lung injury by oxygen toxicity [43, 46]; paraquat
[52]; extensive burns [54]; chronic allograft nephropathy
[48]; and radiation injuries in various organs [49, 50, 55,
68, 69]. In Parkinson’s disease [36, 40] and Alzheimer’s
disease models [42], H2 ameliorates neurodegenerative
changes in the brain. H2 suppresses development of
hypertension in spontaneously hypertensive rats [67].
Furthermore, H2 acts on metabolic pathways to suppress
the development of atherosclerosis in apolipoprotein E
knockout mice [32] and diabetes in db/db mice [53].
In previous studies, H2 was administered by inhalation
[22, 30, 31, 34, 37, 45, 46, 56, 62–64, 66] or dissolved in
water [22, 32–44, 47–55, 57–61, 65, 67–69]. Irrespective
of the administration route, H2 pretreatment could sup-
press oxidation, inflammation, and apoptosis while en-
hancing antioxidant reactions in those models.
Thus far, the precise mechanisms of action involved in
H2 protection from organ injury remain unclear, but it is
thought that the H2 molecule, which freely diffuses into
cells, can react with toxic radicals, such as excess super-
oxide anions (O2
−) generated in mitochondrial respiratory
complexes and hydroxyl radical [22, 23, 70], according
to the following reactions:
O2
− þ H2→H2O2 þ e−
 OH þ H2→ H2O þ  HWH2O þ Hþ þ e
Suppression of oxidative stress by H2 could lead to
suppression of downstream signaling in pathways such
as MAPK [48], MEK-1 [48], NFkB [71], caspase-3 [33,
39], and caspase-12 [33], which would decrease pro-
inflammatory molecule production and apoptosis. This
unique characteristic of H2 is thought to protect cells
and organs from free radical injury. Figure 1 summarizes
the molecular effect of H2 on oxidative stress, inflamma-
tion, and apoptosis.Quantification of H2 amount needed to elicit
biological effects
By quantifying the amount of H2 administered in animal
experiments, it is possible to speculate on the H2 dose
needed for biological effects in vivo. From studies using
H2-enriched drinking water (0.3 to 0.6 mM H2), an ef-
fective H2 dose can be calculated roughly as the product
of H2 concentration and amount of daily water intake.
Given a model using 200-g animals and 20 ml of
enriched water intake daily, the H2 ingested would be 3–
6 × 10−5 mmol/g/day, which would be equivalent to 1.8–
3.6 mmol/day for an average-weight (60 kg) human;
therefore, this may be the dose needed to achieve bio-
logical effects in the clinical setting. Consistent with this
speculation, it was reported that drinking 1.5 L of H2-
enriched water (approximately 0.6 mM) daily for 8 weeks
(that is, 0.9 mmol of H2 ingested daily) reduced urinary
oxidative product (malondialdehyde) and increased anti-
oxidant (superoxide dismutase) levels in subjects with
metabolic syndrome [72]. Accordingly, it is thought that
at least this dosage may be required to elicit any clinical
effect in humans.
H2 application for hemodialysis treatment
H2-enriched water rendered by water electrolysis and
biological effects
With the recent progress of H2 science, therapeutic ap-
plication of H2 has become a clinical challenge [73, 74].
However, practical aspects of how to deliver H2 in a safe
and stable manner at the bedside have been a concern.
In light of this, we have focused on a water electrolysis
technique (Fig. 2).
Water electrolysis gives rise to H2 enrichment near the
electrolysis chamber cathode. The size of an H2 bubble
is thought to be less than 1 μm in diameter [75], and be-
cause of this extremely small size, the half-life of stable
H2 in water is approximately 12 h. The H2 concentration















Fig. 2 Principle of water electrolysis and chemical properties of electrolyzed water at the cathode side. Water electrolysis supplies electrons to
the cathode side. Electrons at the cathode surface react with hydrogen ions (H+) in water to produce theoretical intermediate hydrogen atoms
and the final product, i.e., hydrogen molecules (H2), by a chemical process. Chemical properties of electrolyzed water are characterized by
alkalinity and the presence of dissolved hydrogen molecules (H2)
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presently available commercial electrolysis equipment
[58, 59]. Shirahata et al. [76] demonstrated the unique
chemical characteristics of electrolyzed water near the cath-
ode, such as its antioxidant capacity. The hypoxanthine-
xanthine oxidase system generates superoxide anions (O2
−).
In H2-enriched electrolyzed water, concentrations of O2
−
and, furthermore, of hydrogen peroxide (H2O2) are lower
when compared with control water. DNA breakage in a
mixture of Cu(II) and ascorbic acid was suppressed by this
water. Considered together, these results indicate that H2-
enriched water rendered by an electrolysis system could
elicit chemical reactions in a similar way to the H2 mol-
ecule, as described above.
Studies designed to test the biological activity of electro-
lyzed water have demonstrated tumor antiproliferative ef-
fects [77–79] and antidiabetic actions in a diabetic model
by amelioration of beta cell oxidative injury [80–82]. Drink-
ing enriched water ad libitum ameliorated disuse muscular
atrophy after paralysis in rats [58] and protected against
cardiac and kidney fibrosis by ischemic/reperfusion of
kidney [59] and aging [83] in Dahl SS rats. Further-
more, chronic ad libitum drinking could reduce
lipopolysaccharide-induced neuroinflammation by down-
regulation of TNF-α and upregulation of IL-10 in the brain,
to promote recovery from sickness behavior in mice [84].
Manufacture and delivery of H2 dialysate using water
electrolysis technique
The clinical application of electrolyzed water rendered at
the cathode as HD therapy was reported in 2003 by Hung
et al. in Taiwan [24]. The primary system employed in that
report and our present study is shown in Fig. 3. In studies
from the Taiwanese group, after 6 months of regulartreatments with the HD solution manufactured in this
manner, reductions in serum IL-6 and CRP levels were
seen in 26 patients enrolled in the study [24]. Further-
more, reductions in levels of methemoglobin [25] and
apoptotic lymphocytes [26] were reported in subsequent
studies. These results indicated that clinical application of
electrolyzed water could have some clinical impact. How-
ever, the precise nature of the involvement of H2 in these
studies has remained unclear, since the concept of H2
therapy was not considered at that time.
This issue was clarified by our recent study [29]. The
amount of H2 obtained using this technique depends pri-
marily on the intensity of water electrolysis; however, the
maximum levels of H2 are limited to approximately
200 ppb in the original system because of the increase in
alkalinity with intensification of electrolysis. As shown in
Fig. 3, H2 levels after electrolysis exceeded 200 ppb,
followed by a decline during reverse osmosis to 50 ppb in
the final HD solution. Since the H2 in the HD solution
moves completely into blood through the dialyzer mem-
brane, the delivered dose depends on the flow rate of the
solution. Given that the blood and dialysis solution flow
remain constant, e.g., 200 ml/min for the blood flow, and
500 ml/min for the solution flow, it would be possible to
achieve a 1–3 mmol H2 load in a single HD session.
Clinical experiences of electrolyzed HD and mechanistic
hypothesis of clinical effects by H2 delivery
Reported clinical signs and symptoms delivered by H2-enriched
HD solution and possible mechanistic role of H2 delivery
Since the start of collaborative project over development
of novel hemodialysis system between Nihon Trim Co.,
Ltd. and Tohoku University Graduate School of Medi-














Original personal prototype 
(at Tohoku University)
Changes of H2 levels during 
process of dialysate
Central system
Fig. 3 Original manufacturing process of hemodialysis solution. Tap water is processed by filtration, activated charcoal filtration, and softening,
followed by water electrolysis to deliver H2-rich water for reverse osmosis. There is a progressive decline in H2 levels by this process, and the final
H2 content in dialysate solution is approximately 50 ppb (right figure). Images show the original personal prototype of the electrolyzed HD system
with a single water electrolyzer (left below) and the recent central system for multiple patients that incorporates multiple electrolyzers (left upper)
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laborators have so far observed various clinical benefits
in patients receiving this therapy [29, 85]. H2-enriched
HD solution corrected intra- and inter-dialytic high
blood pressure (Fig. 4a–c), prevented blood flow reduction
by function of dialysis, and increased skin temperature in
cases with peripheral arteriosclerosis (Fig. 5a, b), enhanced
wound healing in a case with ischemic lower limb lesion
(Fig. 5c).
The role of H2-enriched HD solution in these effects
has remained speculative; however, it seems clear that
the delivery of H2 during the HD session is involved with
the mechanism. There is a close relationship between
endothelial dysfunction and oxidative stress. Generation of
oxygen radicals in dialysis patients, e.g., iron infusion and
uremic oxidants, such as indolyl sulfate, could disturb
endothelium-dependent vascular relaxation [86, 87] and ac-
celerate atherosclerosis by enhancing expression of cell ad-
hesion molecules, such as intercellular adhesion molecule-1
(ICAM-1) and vascular cell adhesion molecule-1 (VCAM-
1) of endothelium [88]. During the process of NOS un-
coupling, a characteristic feature of patients with chronic
kidney disease, the superoxide anion reacts with nitric
oxide to inactivate the bioactivity of NO and to generate
peroxynitrite, a potent vasoconstrictive substance [89].
These processes could be involved in the pathological
mechanism of increased blood pressure and decreased
lower limb peripheral blood flow, which result in exagger-
ation of arteriosclerosis obliterans (ASO) and uncontrolledhypertension. Thus, we speculate that H2 as antioxidant
may have suppressed these pathological processes.
There is also a close relationship between enhanced oxi-
dative stress/inflammation and clinical symptoms which as-
sociate with dialysis treatment. Those include dialysis
hypotension, fatigue, and pruritus. Interestingly, we have
observed substantial effects of H2-enriched HD solution on
ameliorating dialysis-related hypotension and subjective
symptoms of dialysis-related fatigue and uremic pruritus.
Dialysis hypotension, which is defined as intra-dialytic
hypotension, is a critical indicator of poor outcome. Fre-
quent episodes of hypotension may induce a noxious in-
flammatory response mediated by the oxidative stress
[90, 91]. It is supposed that abrupt fall in blood pressure
accompanies systemic pathological condition which
mimic acute ischemia reperfusion, inducing inflamma-
tory type M1 macrophage activation [92]. Furthermore,
elevated levels of serum IL-6 in patients with fatigue
[93], and skin micro-inflammation in patients with
uremic pruritus [94, 95], have been reported. Therefore,
it is possible to speculate that H2 may interact with the
underlying pathology of enhanced oxidative stress or in-
flammation by inactivating oxygen radicals, leading to
amelioration of clinical conditions.
Mechanistic hypothesis of clinical effects delivered by H2-
enriched HD solution
As already mentioned, the primary action involved in H2


















Fig. 4 Effect of H2-enriched HD solution on blood pressure (BP) profiles. Changes in diurnal blood pressure differences (ΔBP BP at the start of
dialysis BP in the evening) on hemodialysis day (a) and defined daily dose (DDD) of antihypertensive agents (b). There were significant reductions
in the two parameters at 12 months, compared to baseline, following treatment with H2-enriched HD solution (*p < 0.05) (courtesy of Dr. Hodaka
Suzuki, Higashi-Horai Clinic, Fukushima). Changes in BP before (left) and after (right) regular HD sessions during the 6-month trial of H2-enriched
HD solution (c). There were significant reductions of BP, (p < 0.05, each) (modified from ref. [29])
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radical (Fig. 6). Nevertheless, the observed clinical effects
were not confined to the time period of HD sessions of
three times a week. Upon the fact that elevated H2 level
during HD returns to baseline as soon as the HD stops,
it is therefore difficult to expect prolonged clinical ef-
fects from the chemical point of view of the H2 mol-
ecule. Thus, we think additional mechanism(s) should
be indicated in mediating the clinical effect of H2-
enriched solution.
The redox state is determined by the balance between
the extent of oxidative stress and the activity of antioxi-
dative mechanisms. This is crucially influenced during
the course of an HD session, since there is an enhance-
ment of free radical generation from polymorphonuclear
cells during HD [16], which indicates excess apoptosis
and disturbance of the physiological function of these
cell populations. High plasma MPO, released from in-
jured neutrophils, is an independent risk factor forpatient survival [96]. In chronic kidney disease, mono-
cyte heterogeneity is widely acknowledged, and a grow-
ing body of circumstantial evidence suggests that
intermediate monocytes (CD14(++)CD16(+)) is predis-
posed to secrete pro-inflammatory cytokines [97] and
that polarization of monocyte and macrophage is dis-
turbed, e.g., polarization of becoming dominant macro-
phages is impaired; enhanced pro-inflammatory (M1);
and impaired anti-inflammatory (M2) phenotypes, which
corresponds to the progression of inflammation [98, 99].
Considering these facts, it is important to suppress ex-
cess immune cell injury within the dialyzer, while pre-
serving normal cellular functions of these circulating
cells, which exaggerate the inflammation-prone patho-
logical process of disorders such as atherosclerotic and
ischemic lesions of the vasculature.
H2-enriched solution could benefit patients on HD in
this regard. There is an increase of reduced/oxidized al-
bumin ratio by single HD session using H2-enriched
DHdezylortcelEDHlortnoC




































Fig. 5 (See legend on next page.)
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Fig. 5 Effect of H2-enriched HD solution on changes in blood flow and skin temperature of the lower limb: a clinical case. A case with
progressive decline in lower limb blood flow during regular HD session (left); the decline was suppressed by introduction of H2-enriched HD
solution (right) (courtesy of Dr. Kazumasa Usami, Taigenkai Hospital, Ichinomiya). a A case showing improved aggregated lower limb coldness
with uncontrollable ulceration on stubbed toe after the introduction of H2-enriched HD solution (6 months). b A case showing improved
intractable lower limb ulceration due to obstructive arteriosclerosis after the introduction of H2-enriched HD solution (6 months) (b, c courtesy
of Dr. Hirofumi Nakano, Kashima Hospital, Iwaki)
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creased oxidative injury of polymorphonuclear leuko-
cytes during HD, but the injury was reduced with the
use of H2-enriched solution [27]. Furthermore, available
data indicated that induction of inflammatory M1 mac-
rophages is suppressed by H2 [101]. Taken together, we
speculate that induction of pro-inflammatory condition-
ing of immune cells which enhance oxidative stress dur-
ing the HD session plays a crucial role for the dialysis-
related adverse effects and that amelioration of injured
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leading to apoptosis
Fig. 6 Working hypothesis of the primary mechanism of H2-
enriched HD solution to deliver clinical effects. There is exaggerated
injury of circulating cells, such as mononuclear cells, neutrophils, and
monocytes/macrophages, during HD session. Upon injury, activation
of pro-inflammatory M1 type macrophages dominate and serum
myeloperoxidase is increased, which could enhance inflammation/
oxidative stress furthermore, leading to exaggerate ischemic and
atherosclerotic lesions. H2 could protect these cells from oxidative
injuries during HD session, hence suppressing developments of
systemic pathological conditions, such as endothelial dysfunction,
atherosclerosis, and tissue ischemia by impaired microcirculationcontribute to the appearance of clinical effects. This
point needs to be further elucidated in future studies.
Future directions for H2 therapy in chronic dialysis
patients
Thus far, clinical studies of H2 therapy have been lim-
ited; however, therapeutic intervention with H2 has
great potential to benefit patients on chronic dialysis
treatment. Comorbidities like renal anemia, malnutri-
tion, vascular calcification, and dialysis hypotension
are potential targets for H2 therapy, since all are associated
with enhanced oxidative stress. Currently, whether uremic
micro-inflammation is a cause of erythropoietin-resistant
renal anemia is a matter of debate [102, 103]. Inflamma-
tion stimulates hepcidine production, which suppresses
iron utilization and worsens renal anemia. Malnutrition
observed during long-term dialysis treatment often ac-
companies inflammation, as the so-called malnutrition-
inflammation atherosclerosis (MIA) syndrome [104].
Development of vascular calcification is connected with
the transformation of vascular smooth muscle cells, in
which oxidative stress plays a crucial role [105, 106].
Further studies designed to ascertain the clinical effect







(on  going: UMIN 0000)
Novel system developed
for future clinical trial
H2 level
Appearance
Fig. 7 Possible relationship between dialysate H2 level and clinical effect.
Clinical studies conducted using dialysate solution of approximately
50 ppb H2 showed some clinical effects (UMIN000004857). These effects
become more evident at >100 ppb H2, were diminished at lower levels,
and become obscure at <20 ppb. A novel water electrolyzer capable of
supplying HD solutions with H2 exceeding 200 ppb has been developed
for assessment in a future clinical trial
Nakayama et al. Renal Replacement Therapy  (2016) 2:23 Page 8 of 10optimal effective clinical H2 dose is not known. More-
over, the existence of a dose-response relationship be-
tween the amount of H2 delivered in each HD session
and clinical benefit remains unclear (Fig. 7). This issue
needs to be addressed in order to fully explore the clin-
ical applications of H2 in future trials.
Conclusions
Recent studies have revealed that H2 has a unique
biological capacity to act as an antioxidative and anti-
inflammatory substance. In light of accumulating evi-
dence from animal studies showing protective effects
against organ damage during ischemia and inflamma-
tion, development of H2 treatments for HD patients has
become a challenging clinical goal. An HD system utiliz-
ing a water electrolysis technique that renders large
amounts of H2-enriched water has been developed.
Accumulating findings indicate that the use of an H2-
enriched solution may prove to be a novel approach to
ameliorate dialysis-related complications.
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